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Clinical Investigation
Introduction
Patients with peripheral artery disease (PAD) are at high risk 
for cardiovascular as well as major adverse limb events, 
including acute limb ischemia, need for revascularization, 
and amputation.1–3 There has been increasing interest in 
intensifying antithrombotic therapy in patients with PAD to 
reduce these adverse cardiovascular and limb events. Use of 
new classes of antiplatelet agents, such as vorapaxar (a pro-
tease-activated receptor–1 inhibitor) and third-generation 
thienopyridines, prolonged dual antiplatelet therapy, and 
even the combination of anticoagulation with antiplatelet 
therapy are being actively investigated in patients with PAD. 
However, PAD patients, especially those with critical limb 
ischemia (CLI), constitute a frail population with various 
comorbidities that may increase the risk of major bleeding.4 
The risks and benefits of enhanced antithrombotic therapy 
must therefore be carefully weighed.
To our knowledge, there are no bleeding risk scores that 
have been prospectively validated in patients with PAD. 
However, several independent bleeding risk factors have 
been identified, prospectively validated, and incorporated 
into clinical bleeding risk scores that are used in clinical 
practice for patients with and without baseline atrial fibril-
lation (AF).5 One of the best validated scores is HAS-BLED 
[hypertension, abnormal renal or liver function, stroke, his-
tory of or predisposition to bleeding, labile INR, elderly age 
(>65 years), and drugs or alcohol].6 Lip et al7 recently 
reported that the predictive value of an elevated HAS-
BLED score also applied to individuals from a community 
cohort without baseline AF.
The purpose of the present study was to evaluate the 
bleeding risk profile in an all-comers series of PAD patients 
and to analyze differences in HAS-BLED profiles among 
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Abstract
Purpose: To assess the bleeding risk profile using the HAS-BLED score in patients with symptomatic peripheral artery 
disease (PAD) as a background for intensifying antithrombotic therapy to prevent major adverse cardiovascular and limb 
events. Methods: A post hoc analysis was performed using data from a series of 115 consecutive patients (mean age 
72.4±11.4 years; 68 men) with symptomatic PAD undergoing endovascular revascularization. The endpoint of the study 
was to assess bleeding risk using the 9-point HAS-BLED score, which was previously validated in cohorts of patients 
with and without atrial fibrillation. For the purpose of this study, the original low (0–1), intermediate (2), and high-risk 
(≥3) scores were stratified as low/intermediate risk (HAS-BLED <3) vs high risk (HAS-BLED ≥3). Results: The mean 
HAS-BLED score was 2.76±1.16; 51 (56%) patients had a HAS-BLED score ≥3.0. Patients with PAD Rutherford category 
5/6 ischemia had an even higher mean HAS-BLED score (3.20±1.12). Logistic regression analysis revealed aortoiliac or 
femoropopliteal segment involvement, chronic kidney disease, as well as Rutherford category 5/6, to be independent 
risk factors associated with a HAS-BLED score ≥3. Conclusion: Patients with PAD, especially those presenting with 
Rutherford category 5/6 ischemic symptoms, have high HAS-BLED scores, suggesting increased risk for major bleeding. 
Prospective clinical validation of the HAS-BLED score in patients with PAD may help with the risk-benefit assessment when 
prescribing antithrombotic therapy.
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different PAD subgroups stratified by severity of ischemia 
based on the Rutherford classification.
Methods
Study Design
A post hoc analysis was performed assessing the bleeding 
risk in consecutive patients with symptomatic PAD referred 
to a tertiary vascular center for endovascular revasculariza-
tion between 2014 and 2015. Data collection was performed 
prospectively for performance improvement purposes. 
Approval from the institutional review board was obtained 
to analyze and publish the data. This study was performed 
in accordance with the Declaration of Helsinki8 and the 
Health Insurance Portability and Accountability Act.
Bleeding Risk Assessment
The 9 variables included in the HAS-BLED score, each 
scored as 1 point, were uncontrolled hypertension (systolic 
blood pressure >160 mm Hg), abnormal liver function (aspar-
tate aminotransferase or alanine aminotransferase >3× upper 
limit), abnormal renal function (serum creatinine ≥2.0 mg/
dL), previous stroke, history of bleeding or anemia, labile 
international normalized ratio (INR) (if on vitamin K antago-
nist), age >65 years, drugs (antiplatelet therapy, nonsteroidal 
anti-inflammatory therapy), and alcohol (≥8 standard 
drinks).6,9 In the original HAS-BLED scheme for estimating 
bleeding risks in patients with AF treated with anticoagula-
tion, a HAS-BLED score of 0–1 was considered low risk, a 
score of 2 was intermediate risk, and a score ≥3 was consid-
ered high risk for major bleeding.10 For the purpose of this 
study, the score was stratified only for low/intermediate risk 
(HAS-BLED <3) vs high risk (HAS-BLED ≥3).
Definitions
In this study, anemia was defined as a hematocrit ≤32%. A 
labile INR was defined as <60% of the time in the therapeutic 
range. The assessment of PAD was predicated on the PARC 
(Peripheral Academic Research Consortium) definitions,11 
using the Rutherford classification to describe the severity of 
PAD (0=asymptomatic, 1=mild claudication, 2=moderate 
claudication, 3=severe claudication, 4=rest pain, 5=ischemic 
ulceration, 6=ischemic gangrene). In addition, lesions treated 
were categorized as aortoiliac, femoropopliteal, infrapopliteal, 
or multisegment if affecting >1 of these segments.
Patient Population
Between 2014 and 2015, 115 consecutive patients (mean 
age 72.4±11.4 years; 68 men) with symptomatic PAD 
underwent endovascular revascularization at our center. 
Table 1 provides detailed information on the baseline demo-
graphics and risk factors of these patients, and Table 2 lists 
the arterial segments involved and whether patients had 
prior revascularization.
Statistical Analysis
Categorical variables are presented as numbers (percent-
ages) and were compared using a chi-square test; continu-
ous variables were reported as means ± standard deviation. 
A homogenous distribution was assessed using an indepen-
dent t test or the Kolmogorov-Smirnov test. Independent 
variables associated with a high risk for bleeding (HAS-
BLED ≥3) were identified by logistic regression analysis; 
the results are presented as the odds ratio (OR) and 95% 
Table 1. Baseline Demographics and Bleeding Risk Factors of 
the 115-Patient Group.a
Women 47 (40.9)
Age, y 72.4±11.4
GFR, mL/min/1.73 m2 63.7±39.1
Hypertension 107 (93.0)
 Uncontrolled 57 (49.6)
Diabetes mellitus 56 (48.7)
 Insulin-dependent 28 (24.3)
Liver dysfunction 3 (2.6)
Active tobacco 25 (21.7)
Former tobacco 43 (37.4.)
Alcohol 4 (3.5)
Drugs 2 (1.7)
Coronary artery disease 48 (41.7)
Congestive heart failure 17 (14.8)
Transient ischemic attack 7 (6.1)
Stroke 16 (13.9)
CKD stage
 1 (GFR >90) 20 (17.4)
 2 (GFR >60 to <90) 30 (26.1)
 3 (GFR >30 to <60) 38 (33.0)
 4 (GFR >15 to <30) 14 (12.2)
 5 (GFR <15 or dialysis) 13 (11.3)
Peripheral artery disease 69 (60.0)
Bleeding history or predisposition 28 (24.3)
Low platelet count 5 (4.3)
Rutherford category
 1 0 (0.0)
 2 14 (12.2)
 3 33 (28.7)
 4 23 (20.0)
 5 39 (33.9)
 6 6 (5.2)
Abbreviations: CKD, chronic kidney disease based on glomerular 
filtration rate (GFR) calculated by Cockcroft-Gault formula.
aContinuous data are presented as the means ± standard deviation; 
categorical data are given as the counts (percentage).
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confidence interval (CI). A p<0.05 was considered to indi-
cate statistical significance. Statistical analysis was per-
formed using STATA software (version 14.0; StataCorp, 
College Station, TX, USA).
Results
The overall mean HAS-BLED score across the 115 patients 
was 2.76±1.16. There were no patients with a HAS-BLED 
score of 0; 51 (55.7%) patients had a HAS-BLED score ≥3 
(Table 2). Stratifying the mean HAS-BLED scores accord-
ing to Rutherford categories (RC), patients with tissue loss 
(ie, RC 5/6) had a significantly higher HAS-BLED score 
compared to patients with RC 2–4 symptoms (3.20±1.12 vs 
2.47±1.10, p<0.001; Figure 1). The mean HAS-BLED 
score in patients with RC 4 ischemia was more similar to 
patients with RC 2–3 symptoms and significantly lower 
compared to patients with RC 5/6 ischemia (p<0.001, 
Figure 1). Similarly, a HAS-BLED score ≥3 was more com-
mon in patients with RC 5/6 than in patients with RC 2–4 
(73.3% vs 44.3%, p=0.002). The main clinical variables 
represented in HAS-BLED that drove these differences 
included advanced renal insufficiency (creatinine >2.0 mg/
dL) and a history of bleeding or predisposition to bleeding 
(p≤0.004 for both).
Logistic regression analysis revealed that involvement 
of the femoropopliteal (OR 3.17, 95% CI 1.03 to 9.75, 
p=0.04) or aortoiliac segments (OR 3.15, 95% CI 1.05 to 
9.41, p=0.04), RC 5/6 ischemia (OR 3.52, 95% CI 1.39 to 
8.95, p=0.008), and chronic kidney disease stage ≥2 defined 
by a glomerular filtration rate <60 mL/min/1.73 m2 (OR 
3.37, 95% CI 1.42 to 8.00, p=0.006) were independent risk 
factors for a HAS-BLED score ≥3.
Discussion
The current study shows that patients with symptomatic 
PAD had an elevated HAS-BLED score, which was even 
higher in the setting of ischemic tissue loss. Almost three 
quarters of patients with RC 5/6 ischemia had a HAS-BLED 
score ≥3, suggesting that this PAD subgroup is at increased 
risk of major bleeding compared to patients with RC 2–4 
symptoms.
This was a qualitative rather than quantitative study. We 
did not have long-term follow-up data for patients and could 
not capture actual bleeding events. The absolute risk of major 
bleeding events therefore cannot be derived from our data. 
However, to put the HAS-BLED scores into perspective, one 
may consider the performance of HAS-BLED in other patient 
populations. In a cohort of “real world” patients with AF 
receiving anticoagulation, a HAS-BLED score ≥3.0 carried a 
3-fold increase in the rate of major bleeding (defined as hospi-
talization or death from major bleeding) compared to patients 
with a HAS-BLED score of 0 or 1 (8.1 vs 2.6 events per 100 
person-years, respectively).10 The predictive value of HAS-
BLED also applies in patients without baseline AF.7 In the 
Chin-Shan Community Cohort study,7 the risk for intracranial 
hemorrhage rose with increasing HAS-BLED scores, with a 
C-statistic of 0.72. In that cohort study, 40% of individuals 
had a HAS-BLED score of 0, and 4.3% had a HAS-BLED 
Table 2. Level of Disease, Prior Revascularization, Amputation, 
and HAS-BLED Scores in the 115 Study Patients.a
Level of disease
 Aortoiliac 36 (31.3)
 Femoropopliteal 88 (76.5)
 Infrapopliteal 51 (44.3)
 Multisegment 56 (48.7)
Prior amputation
 Minor (below ankle) 14 (12.2)
 Major 6 (5.2)
Prior revascularization
 Endovascular 48 (41.7)
 Surgical 20 (17.4)
HAS-BLED score
 0 0 (0.0)
 1 16 (13.9)
 2 35 (30.4)
 3 34 (29.6)
 4 23 (20.0)
 5 5 (4.4)
 6 2 (1.7)
Abbreviations: HAS-BLED, hypertension, abnormal renal or liver 
function, stroke, history of or predisposition to bleeding, labile INR, 
elderly age (>65 years), and drugs or alcohol.
aData are given as the counts (percentage).
Figure 1. Mean HAS-BLED scores according to Rutherford 
category. HAS-BLED, hypertension, abnormal renal or liver 
function, stroke, history of or predisposition to bleeding, labile 
INR, elderly age (>65 years), and drugs or alcohol.
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score ≥3.0. The rate of intracranial hemorrhages increased 
with higher HAS-BLED scores: 0.2 events per 1000 patient-
years for a HAS-BLED score of 0 and 4.1 intracranial bleeds 
per 1000 patient-years for a HAS-BLED score ≥3. In our 
study, no patients with PAD had a HAS-BLED score of 0, and 
more than half had a HAS-BLED score ≥3.0. We interpret 
these findings as an indication that patients with symptomatic 
PAD, especially those with ischemic ulceration or gangrene, 
are at increased risk of major bleeding, including intracranial 
hemorrhage.
To further understand the significance of the elevated 
HAS-BLED among patients with PAD, we determined the 
HAS-BLED score in a cohort of age- and gender-matched 
patients (n=39) without PAD. These patients did not have a 
prior diagnosis of PAD, had no lower extremity symptoms 
on exertion, and had normal bilateral pedal pulses on physi-
cal examination. The proportion of non-PAD patients who 
had a HAS-BLED score >3 was 5.1% (2/39) compared with 
26.1% (30/115) in the PAD cohort (p=0.005).
An interesting finding in our study is that HAS-BLED 
scores were significantly higher in patients with Rutherford 
category 5/6 ischemia compared with RC 2–4 patients. One 
could have anticipated that patients with RC 4 (ischemic 
rest pain) would have had a similar HAS-BLED profile 
compared to patients with RC 5/6 symptoms, as all of these 
patients are grouped into the standard definition of CLI. 
However, we found that RC 4 patients had a mean HAS-
BLED score similar to patients with intermittent claudica-
tion (RC 2/3). We hypothesize that RC 4 patients are 
biologically more similar to patients with intermittent clau-
dication (RC 2/3) and that they “shift” to an advanced stage 
with CLI due to an acute-on-chronic event. In contrast, RC 
5/6 may represent more of a chronic status with CLI.
Conclusion
Patients with symptomatic PAD have elevated HAS-BLED 
scores compared with the general population. Even among 
PAD patients, those with ischemic ulceration or gangrene 
(ie, RC 5/6) have higher HAS-BLED scores compared to 
the other PAD subgroups. These observations suggest that 
PAD patients are at increased risk of bleeding complica-
tions. The application of HAS-BLED or similar bleeding 
risk scores warrant further scrutiny, including prospective 
validation for use in PAD patients and would provide a 
great clinical tool to assess the risk-benefit ratio of anti-
thrombotic therapy in PAD patients.
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